Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service ERCP & endoscopic ultrasound cases in Louisiana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (240 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 22 | 1,892 | 42% |
| 2020 | 21 | 1,406 | 45% |
| 2021 | 20 | 1,380 | 51% |
| 2022 | 22 | 1,348 | 54% |
| 2023 | 24 | 1,511 | 58% |
| 2024 | 24 | 1,549 | 60% |
| 2025 from claims | – | 1,513 1,389–1,601 | 61% |
| 2026 forecast | – | 1,519 1,337–1,753 | 62% |
| 2027 forecast | – | 1,535 1,312–1,829 | 63% |
| 2028 forecast | – | 1,550 1,294–1,898 | 63% |
| 2029 forecast | – | 1,565 1,278–1,963 | 64% |
| 2030 forecast | – | 1,580 1,266–2,024 | 65% |
Biliary stenting, stone extraction, EUS with FNA; the advanced-endoscopy call point. Professional codes (what the surgeon bills): CPT 43264, 43274, 43260, 43259, 43242, 43266.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 76% of the cases CMS names in Louisiana; 12 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 39% inpatient hospital, 49% hospital outpatient, 11% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 119 | 8,114−0.6%/yr | −0.6%/yr | 3.7 | 6% | 9,910 in 2030+3.4%/yr |
| Texas | 130 | 7,585−0.2%/yr | −0.2%/yr | 3.6 | 6% | 10,200 in 2030+5.1%/yr |
| North Carolina | 52 | 3,646−1.8%/yr | −1.8%/yr | 3.8 | 5% | 3,960 in 2030+1.4%/yr |
| Virginia | 48 | 3,175+1.2%/yr | +1.2%/yr | 3.1 | 0% | 3,690 in 2030+2.6%/yr |
| Maryland | 36 | 2,499+2.9%/yr | +2.9%/yr | 2.9 | 1% | 3,770 in 2030+7.1%/yr |
| South Carolina | 38 | 2,414+3.9%/yr | +3.9%/yr | 3.6 | 1% | 3,510 in 2030+6.4%/yr |
| Tennessee | 45 | 1,981−2.7%/yr | −2.7%/yr | 2.9 | 7% | 2,310 in 2030+2.6%/yr |
| Georgia | 39 | 1,940−4.2%/yr | −4.2%/yr | 2.3 | 0% | 2,330 in 2030+3.1%/yr |
| Kentucky | 24 | 1,609−3%/yr | −3%/yr | 3.6 | 2% | 1,660 in 2030+0.5%/yr |
| Alabama | 21 | 1,343−4.1%/yr | −4.1%/yr | 3.1 | 11% | 1,700 in 2030+4%/yr |
| West Virginia | 12 | 913−4.3%/yr | −4.3%/yr | 4.5 | 0% | 1,000 in 2030+1.5%/yr |
| Oklahoma | 13 | 913−5.4%/yr | −5.4%/yr | 1.9 | 0% | 1,080 in 2030+2.9%/yr |
| Arkansas | 12 | 721−1.7%/yr | −1.7%/yr | 1.9 | 0% | 990 in 2030+5.4%/yr |
| District of Columbia | 6 | 706−0.3%/yr | −0.3%/yr | 11.4 | 0% | 760 in 2030+1.2%/yr |
| Mississippi | 11 | 634−4%/yr | −4%/yr | 1.7 | 5% | 710 in 2030+1.9%/yr |
| Delaware | 10 | 417−1.5%/yr | −1.5%/yr | 2.5 | 0% | 470 in 2030+2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 259 | 49,097−5.9%/yr | −5.9%/yr | 125.41.1× | 50% | 47,000 in 2030−0.7%/yr |
| Bronchoscopy & lung nodule | 18 | 1,193+5.7%/yr | +5.7%/yr | 3.00.9× | 0% | 2,510 in 2030+13%/yr |
ERCP & endoscopic ultrasound in every state, and its device makers · Every procedure market in Louisiana · Every state · Compare with Florida
Capsovision leads with 44% of company spending on these surgeons in 2025, +43 pts on 2024.
In 2025, 14 companies reported engagement with Louisiana’s surgeons worth $24K in consulting, speaking, meals and travel tied to these products, about $991 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.